CALGARY, Sept. 14, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2016 and related Management's Discussion and Analysis with Canadian securities regulatory authorities. Copies of these documents may be obtained online at www.sedar.com, or the Company's website, www.resverlogix.com, or by emailing firstname.lastname@example.org.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
For further information please contact:
SOURCE Resverlogix Corp.